sion of 2 time periods more than 10 years apart provides insight into changes in treatment choices over time based on age, stage, and grade. The aim of this study was to assess the associations of stage, grade, and age with the primary treatment of PCa patients in the Canton of Zurich, Switzerland comparing the incidence years 2000/2001 and 2012/2013, and to estimate RS based on these factors for patients diagnosed in 2000/2001.
Materials and Methods

Study Population
The epidemiological Cancer Registry Zurich and Zug is the largest in Switzerland covering roughly 1.6 million inhabitants. The Registry was established in 1980 to register every cancer patient in the canton of Zurich (and since 2011 in the canton of Zug). The Registry is almost complete; the percentage of death certificate only (DCO) cases is 1.9% for the period of 1988-2012, and the percentage of morphologically verified cases is 93.2% [9] . We included PCa patients who lived in the Canton of Zurich at the time of diagnosis. PCa was defined based on the ICD-10 coding (International Statistical Classification of Diseases and Related Health Problems). To compare former and current treatment choices, we extracted the data of men diagnosed in the years 2000/2001 and 2012/2013. We restricted our data to patients with PCa as the first primary cancer diagnosis and excluded DCO cases and cases diagnosed at autopsy. Of 1,667 PCa cases in 2000/2001, we excluded 78 DCO cases (4.7%) and 48 cases that were diagnosed at autopsy (2.9%). In 2012/2013, of 1,750 PCa cases, 14 DCO cases (0.8%) and 131 cases diagnosed at autopsy (7.5%) were excluded. Hence, for 2000/2001 we finally included 1,541 and for 2012/2013 1,605 PCa patients. We obtained data pertaining to the patients' vital status from the Citizen Services Departments in the Canton of Zurich. Patients diagnosed in 2000/2001 were followed until death or for a maximum of 10 years after diagnosis, whichever came first. The Registry systematically registers the type of cancer, name, date of birth, sex, place of residence, stage and grade of the tumor, and information regarding treatment. The stage of the tumor was classified based on the TNM classification. We restricted the TNM classification to the T-classification, hereafter called stage, which describes the tumor extent. The pathological stage was used if available; otherwise the clinical stage was used. In many cases, we only had knowledge about the tumor grade but not the corresponding Gleason score; hence, the PCa tumor grade was used. Only the primary treatment of a patient was considered. We distinguished between surgical procedures, radiotherapy, and androgen deprivation therapy (ADT). As we cannot directly distinguish between AS and WW, we defined 1 treatment group for AS/WW. Age was divided into 4 groups (< 60, 60-69, 70-79, and > 79 years).
Statistical Methods
In order to handle missing values for stage and grade, multiple imputation with chained equations (MICE) was applied to impute the incomplete data [10, 11] . The imputation model includes the incomplete variables stage and grade and the complete variables date of diagnosis, age at diagnosis, survival time, vital status, and primary treatment. The missing variables were imputed using a multinomial logit model. Since the fraction of missing stage information in the years 2000/2001 and 2012/2013 was approximately 15 and 5%, respectively, and missing grade information was 7% in both periods, we created 20 complete datasets. For each dataset, the analyses were performed separately and merged afterwards using Rubin's rule [12] . After imputation, we tested for a trend in treatment choices by age, stage, and grade using a chi-squared test for trends in proportions. Multinomial logistic regression analyses were used to assess the associations of stage, grade, and age with treatment choices.
For the diagnosis years 2000/2001, we performed RS analyses. RS is defined as the ratio of the observed and the expected survival. The expected survival was estimated from a comparable general population using the Ederer II approach [13] with a life table for the Canton of Zurich [14] . Mortality rates in the Canton of Zurich for each year were available in 22 age groups. To interpolate the abridged life table, the Elandt-Johnson method was applied [15] . Stratified analyses were conducted by age groups, stage, grade, and primary treatment. All statistical analyses were performed in R (version 3.2.2). The R package 'MICE' [16] was used to impute the missing data, the package 'nnet' [17] to perform the regression models, and the package 'relsurv' [18] to estimate RS rates.
Results
The mean age at diagnosis of men diagnosed in 2000/2001 was 70.1 years (standard deviation (SD) = 9.0, median = 70.0, interquartile range = 12.0). During the follow-up period of 10 years, 833 (54%) of 1,541 men died and 27 (1.8%) were lost to follow-up. The average length of follow-up was 7.7 years (SD = 3.2, median = 9.9, interquartile range = 4.6). For the diagnosis years 2012/2013, the mean age at diagnosis was 69.8 years (SD = 9.7, median = 69.0, interquartile range = 12.0). Table 1 Table 2 presents the associations of age, stage, and grade with treatment choices using the imputed dataset for patients diagnosed in 2000/2001 and 2012/2013. All results were adjusted for age, grade, and stage. In 2000/2001, age was associated with treatment choices indicating that older patients were less likely to have surgery. In addition, AS/WW was more likely a treatment choice for older patients and patients with an early-stage tumor. Furthermore, higher tumor grade was associated with higher odds of receiving ADT compared to surgery. Interestingly, in 2012/2013, age was not associated with treatment choice anymore except for ADT (higher age associated with higher odds of ADT versus surgery). In 2000/2001, there was no association between PCa stage and active treatment, but in 2012/2013, having a stage T4 versus T1 tumor was significantly associated with ADT versus surgery. Figure 1 illustrates the RS of patients diagnosed in 2000/2001 using the imputed data stratified by age, stage, grade, and primary treatment. Overall, the 1-, 5-, and 10-year RS was 98.5% (95% confidence interval (CI) 97.3-99.6), 93.8% (95% CI 91.2-96.4), and 91.7% (95% CI 87.8-95.7), respectively. The RS of men younger than 80 years was close to 100%, whereas men aged 80 years and older had a lower RS. RS was highest for men diagnosed with a T1 Stratification by primary treatment choices revealed that the RS of patients who underwent surgical procedures or radiotherapy was approximately 100% within 10 years, whereas the RS of patients who underwent ADT was considerably lower. The RS of men under AS/WW decreased over time.
Discussion
In this study among PCa patients of a Swiss cancer registry, we observed associations of age, stage, and grade with treatment choices. In general, older-aged patients were more likely to receive ADT or AS/WW versus surgery than younger patients, and men with a T1 tumor were more likely to be under AS compared to men with a higher-stage tumor. Additionally, we noted a shift in the association of age with treatment choices such that in 2000/2001, patients older than 70 years were significantly more likely to undergo radiotherapy or to be under AS/WW compared to surgery, which we did not observe in 2012/2013 (table 2) . Furthermore, the earlier PCa is diagnosed, the higher the RS for patients. RS was highest for patients treated with surgery or radiotherapy and considerably lower for patients undergoing ADT.
These findings are in line with former and current guidelines. The 2001 guideline of the European Association of Urology (EAU) [4] and the 2003 guideline of the European Society for Medical Oncology (ESMO) [5] recommended surgery and radiotherapy for men with localized PCa who were younger than 70 years of age, whereas AS/WW was recommended for men with localized PCa over 70 years old. For men with advanced disease and for unfit patients, ADT is a treatment option. Our results reflect these former recommendations, illustrating that surgery was more frequent in men younger than 70 years and AS/WW was an option for men older than 70 years. Comparing the former guidelines with the current EAU guideline from 2013 [7] and the EMSO guideline from 2015 [6] , a major change is the recommendation of AS also for patients with localized PCa who have a life expectancy of more than 10 years. Indeed, the number of men under AS/WW in the younger age groups increased remarkably in our study. Our results show that treatment decisions depend on age; however, in addition, they should also depend on life expectancy, which we cannot reflect in our study. Furthermore, we observed that ADT was more frequently a treatment option for advanced-stage and undifferentiated tumors. Between 2000/2001 and 2012/2013, the number of men with a T4 tumor treated with ADT increased from 16 to 37%.
We observed a stage migration from T2 to T1 tumors from 2000/2001 to 2012/2013. This reflects the growing use of PSA screening in Switzerland [19] , which leads to a higher proportion of men having a T1 tumor. We hypothesize that, despite the debate about the benefits of PSA screening, men are more aware of PCa and still perform opportunistic testing.
A study from the Munich Cancer Registry in Germany covering the years 1990-2010 reported an increase in men undergoing surgery from 45% in 2000-2004 to 53% in 2005-2010 [20] . Our results confirm the increasing use of surgery, although the proportions in our study are slightly higher. We speculate that the robot-assisted da Vinci surgical system, first introduced in 2000 [21] , could have an impact on the increasing number of surgeries. The proportion of men who underwent ADT was much higher in Germany, namely 29% in 2000-2004 and 21% in 2005-2010, while the proportion remained constant at 9% in the Canton of Zurich. However, in the Munich Cancer Registry, the number of men under AS/WW was around 20% in both periods, whereas we observed about 28% in the Canton of Zurich. Evaluating the RS of PCa patients in Germany revealed an overall 10-year RS of 91% [22, 23] , and studies based on US SEER data observed a 10-year RS of PCa patients between 95 and 100% [23, 24] . The RS in our study is comparable with that observed in Germany, but is lower than in the US. Different incidence and stage distributions in the US and Germany may partly explain these differences [23] . In the US, PSA screening was used more frequently and introduced earlier compared with Switzerland or Germany. An earlier detection due to PSA screening and over-diagnosis of asymptomatic PCa postpone the time of death and may result in a longer survival time (lead-time bias) [25] .
The results of this study are in line with previous studies from the US and the UK that also reported highest RS for men 60-74 years old [24, 26] (fig. 1A ). This observation might be explained the fact that more men in their 60s or 70s had a PSA test [26] .
Several German, US, and UK studies observed that the RS of men with localized PCa was higher than 100% and increased over time [22, 24, 26] . We also observed an RS of about 100% for men with a T1 or T2 tumor ( fig. 1B ) and an RS of over 100% for men with grade 1 tumors (fig. 1C) . These high RS rates probably indicate a selection bias [22] . Firstly, PSA screening tends to be used more often by men with a more health-conscious behavior, which implies that men having an early-stage PCa are generally healthier than men of the general population [27] . Secondly, men diagnosed with an early-stage tumor might improve their lifestyle as consequence of this diagnosis, e.g. quit smoking, engage in physical activity more frequently, or change their diet [28] . A third reason could be the influence of the socioeconomic status of the patients. Liu et al. [29] reported that a high socioeconomic status was associated with higher odds of performing a PSA test. Rapiti et al. [30] reported similar results for Geneva, Switzerland.
The low RS of men receiving ADT ( fig. 1D ) is likely explained by the more frequent ADT use in older men or in men with advanced-stage PCa. Furthermore, ADT could lead to side effects that are related to a higher risk of all-cause mortality [31] .
A strength of this study is the almost complete coverage of PCa patients in the Canton of Zurich. should not have been assigned anymore because this diagnosis is poorly reproducible even for experts; in addition, a Gleason score 2 may today be referred to as adenosis, not as PCa. Consequently, grade 1 tumors diagnosed in the years 2000 and 2001 would possibly receive a higher grading today [33] . Furthermore, our treatment information is limited so that we cannot clearly distinguish between AS or WW. In addition, we only have information about radiotherapy and cannot further subdivide into external beam radiation therapy and brachytherapy. Moreover, we investigated only the first primary treatment. Treatment combinations, neoadjuvant, adjuvant, or postoperative therapies were not reflected in our study. We could also not consider delayed treatments after AS/ WW. Furthermore, the presence of other chronic diseases at the time of diagnosis may affect the treatment choices. Unfortunately, we do not have information on co-morbidities of the PCa patients.
Conclusion
In conclusion, our study showed an association of age, stage, and grade with treatment choices as recommended in official guidelines. We illustrated that today AS/WW is not only an option for patients with a life expectancy shorter than 10 years but also for younger men having localized PCa. An increase in AS/WW might help to counteract over-treatment especially of younger patients and those with early-stage PCa. Our findings are consistent with results from previous studies stating that PCa patients have a good RS if the cancer is diagnosed at an early stage. An RS above 100% probably indicates a selection bias due to PSA screening, which tends to be more often used by men with a more health-conscious behavior.
Disclosure Statement
This work was supported by the Kurt und Senta Hermann-Stiftung. Manuela Limam was supported by the Cancer League Zurich.
